Clinical Trial Update: IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating Xeomin (incobotulinumtoxinA) for the treatment of focal hand dystonia, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Hand Dystonia

Drugs mentioned

• XEOMIN (INCOBOTULINUMTOXINA)

Snippet

Sponsor: Alain Kaelin | Conditions: Focal Hand Dystonia | Phase 3 | Status: RECRUITING